Novartis India Ltd vs Panacea Biotec Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 14, 2026

Key Highlights

The Latest Trading Price of Novartis India Ltd is ₹ 1303 as of 12 Jun 15:30 . The P/E Ratio of Novartis India Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Panacea Biotec Ltd changed from 0.8 on March 2022 to 0 on March 2025 . This represents a CAGR of -100.00% over 4 years The Market Cap of Novartis India Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Panacea Biotec Ltd changed from ₹ 1086 crore on March 2021 to ₹ 2699 crore on March 2025 . This represents a CAGR of 19.96% over 5 years The revenue of Novartis India Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Panacea Biotec Ltd for the Mar '26 is ₹ 172.01 crore as compare to the Dec '25 revenue of ₹ 170.24 crore. This represent the growth of 1.04% The ebitda of Novartis India Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Panacea Biotec Ltd for the Mar '26 is ₹ 7.83 crore as compare to the Dec '25 ebitda of ₹ 16.79 crore. This represent the decline of -53.37% The net profit of Novartis India Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Panacea Biotec Ltd changed from ₹ -15.88 crore to ₹ -1 crore over 8 quarters. This represents a CAGR of -74.91% The Dividend Payout of Novartis India Ltd changed from 118.09 % on March 2021 to 61.15 % on March 2025 . This represents a CAGR of -12.33% over 5 yearsThe Dividend Payout of Panacea Biotec Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Novartis India Ltd

Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the world's second largest pharmaceutical company was incorporated on 13 December 1947.
The Company is engaged in manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare; it operates into four segments such as Pharmaceuticals, Generics, Over the Trade Counter and Animal Health. The origin of Novartis is linked to the origin of three distinct companies namely Geigy, Ciba, and Sandoz.
The history of Geigy goes back to the middle of the 18th century, Ciba was founded around 1860, and Sandoz was set-up in 1886.
In 1970 Ciba and Geigy merged to form Ciba-Geigy Ltd. Sandoz and Ciba-Geigy Ltd continued as separate entities for the next 25 years.
In 1996, in one of the largest corporate mergers in history Sandoz and Ciba-Geigy Ltd.

About Panacea Biotec Ltd

India's leading research-based health management company with established research, manufacturing and marketing capabilities are collectively known as Panacea Biotec Limited (PBL), which was incorporated on February 2, 1984 under the name of Panacea Drug (P) Limited.
The name of the Company was changed to the present 'Panacea Biotec Limited' in 1993. A second largest vaccine producer in India has the product portfolio of highly innovative prescription products in important therapeutic areas such as pain management, diabetes management, renal-disease management, anti-osteoporosis, anti-tubercular, gastro-intestinal care products and vaccines. The plant for vaccines production (Radicura Pharma) and pharmaceutical formulations plant (Panacea Drug P Ltd) at New Delhi were established during the year 1988 and 1989 respectively.

FAQs for the comparison of Novartis India Ltd and Panacea Biotec Ltd

Which company has a larger market capitalization, Novartis India Ltd or Panacea Biotec Ltd?

Market cap of Novartis India Ltd is 3,219 Cr while Market cap of Panacea Biotec Ltd is 3,291 Cr

What are the key factors driving the stock performance of Novartis India Ltd and Panacea Biotec Ltd?

The stock performance of Novartis India Ltd and Panacea Biotec Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Novartis India Ltd and Panacea Biotec Ltd?

As of June 14, 2026, the Novartis India Ltd stock price is INR ₹1303.85. On the other hand, Panacea Biotec Ltd stock price is INR ₹537.3.

How do dividend payouts of Novartis India Ltd and Panacea Biotec Ltd compare?

To compare the dividend payouts of Novartis India Ltd and Panacea Biotec Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.